Consensus CONMED Corporation Deutsche Boerse AG

Stocks

EC8

US2074101013

Medical Equipment, Supplies & Distribution

Market Closed - Deutsche Boerse AG 15:55:02 2026-08-18 EDT			5-day change	1st Jan Change
42.60 ^EUR	+0.95%		-0.93%	+21.71%

07-30	CONMED Q2 Adjusted Earnings, Revenue Rise; 2026 Guidance Raised	MT
07-30	CONMED Corporation, Q2 2026 Earnings Call, Jul 29, 2026

Evolution of the Average Target: CONMED Corporation

Evolution of the Target Price: CONMED Corporation

Changes in Analyst Recommendations: CONMED Corporation

713950d65e777e03e0218ad274a844.XU4bWXq4zBfahMZn6dbruRT56SoHlXEw6CUdoOIvZVY.EBliLBjf9XKI9ZwVn4-t-2SKoR1_-R9x2Vxc5pFjMCQ8DFNvHP6VQoXBjw~9819b95383457f9a77f0fd42e7a42458

Analysts' recommendations: CONMED Corporation

07-09	BMO Capital Initiates CONMED at Market Perform With $36 Price Target	MT
06-29	CONMED Lagging Medtech Peers as Growth Slows, BofA Securities Says	MT
06-29	BofA Downgrades CONMED to Underperform From Neutral, Keeps $40 Price Target	MT
05-18	BofA Securities Adjusts CONMED Price Target to $40 From $52	MT
03-17	Piper Sandler Downgrades CONMED to Neutral From Overweight, Adjusts PT to $39 From $55	MT
25-06-12	Conmed Shares Fall After Needham Downgrade	MT
25-06-12	Needham Downgrades CONMED to Hold From Buy, Removes $61 Price Target	MT
25-04-28	Stifel Downgrades CONMED to Hold From Buy, Adjusts Price Target to $55 From $75	MT
25-02-06	JPMorgan Downgrades CONMED to Neutral From Overweight, Adjusts Price Target to $70 From $85	MT
24-08-01	Needham Adjusts CONMED's Price Target to $97 From $106, Keeps Buy Rating	MT
24-07-25	Needham Trims Price Target on CONMED to $106 From $107, Keeps Buy Rating	MT
24-04-25	Wells Fargo Adjusts Price Target on CONMED to $77 From $98, Maintains Equalweight Rating	MT
24-04-25	Needham Lowers Price Target on CONMED to $107 From $129, Notes Slight Guidance Cut Due to Currency, Keeps Buy Rating	MT
24-02-01	Needham Adjusts Price Target on CONMED to $129 From $119, Maintains Buy Rating	MT
24-02-01	JPMorgan Cuts CONMED Price Target to $115 From $135, Maintains Overweight Rating	MT
23-10-27	Piper Sandler Adjusts Price Target on CONMED to $130 From $145, Maintains Overweight Rating	MT
23-10-26	Wells Fargo Cuts Price Target on CONMED to $107 From $123, Maintains Equalweight Rating	MT
23-07-27	Needham Adjusts Price Target on CONMED to $140 From $139, Maintains Buy Rating	MT
23-07-27	Keybanc Adjusts Price Target on CONMED to $141 From $131, Maintains Overweight Rating	MT
23-06-05	Needham Raises Price Target on CONMED to $139 From $135, Keeps Buy Rating	MT
23-05-22	CL King Starts CONMED at Buy With $140 Price Target	MT
23-04-27	Piper Sandler Raises CONMED's Price Target to $128 From $118, Maintains Overweight Rating	MT
23-04-27	Wells Fargo Adjusts Price Target on CONMED to $119 From $96, Maintains Equal-Weight Rating	MT
23-04-27	Needham Adjusts Price Target on CONMED to $135 From $122, Reiterates Buy Rating	MT
23-04-27	Keybanc Adjusts Price Target on CONMED to $131 From $124, Maintains Overweight Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ABBOTT LABORATORIES					+8.18%
	MEDTRONIC PLC					+8.65%
	CENCORA, INC.					+19.22%
	HOYA CORPORATION					+15.73%
	BECTON, DICKINSON AND COMPANY					+6.77%
	DEXCOM, INC.					+6.04%
	MEDLINE INC.					+27.91%
	WEST PHARMACEUTICAL SERVICES, INC.					+16.77%
	TERUMO CORPORATION					+18.7%
	Average					+14.22%
	Weighted average by Cap.					+11.70%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

49.26USD

Average target price

45.50USD

Spread / Average Target

-7.63%

High Price Target

49.00USD

Spread / Highest target

-0.53%

Low Price Target

43.00USD

Spread / Lowest Target

-12.71%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

BMO Capital
BofA Securities
Piper Sandler
Needham & Co.
Stifel Nicolaus
JPMorgan Chase
Wells Fargo Securities
KeyBanc Capital Markets
CL King
Jefferies & Co.
UBS
Barclays